Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights

Nov 08, 2022 4:09pm EST

Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock

Sep 19, 2022 4:05pm EDT

Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference

Sep 08, 2022 4:05pm EDT

Baudax Bio Announces Closing of $6.2 Million Public Offering

Sep 01, 2022 2:56pm EDT

Baudax Bio Announces Pricing of $6.2 Million Public Offering

Aug 29, 2022 10:04pm EDT

Baudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe pain

Aug 22, 2022 8:00am EDT

Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights

Aug 11, 2022 7:00am EDT

Baudax Bio Announces Dosing of First Cohort in First-in-Man, Phase I Clinical Study Evaluating BX2000

Jun 01, 2022 8:00am EDT

Baudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences Conference

May 18, 2022 8:00am EDT

Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 17, 2022 7:00pm EDT